When Tat CPP is fused with BID, it should be delivered to cancer cells in a controlled manner that would likely enhance TRAIL efficacy, as consistent with results of a study showing that Tat CPP could efficiently sensitize prostate PC3 cells and non-small human lung cancer A549 cells to TRAIL [142]. This evidence concerns the gene TAT and cancer.